The BIOSECURE Act, first introduced in Congress last year, has now been reintroduced for inclusion in Senate’s draft of the annual National Defense Authorization Act ( NDAA ) for FY2026. The NDAA is a must-pass piece of legislation that often ends up as a vehicle for moving many different bills forward—and reflects a complex process that epitomizes DC horse-trading. As originally proposed, the Act sought to restrict federal funding and contractual relationships between the U.S. government and any entities engaging with “biotechnology companies of concern” for the procurement of equipment or services. In practice, the Act would force biopharmaceutical companies to sever ties with Chinese biotechs. The reintroduced version retains much of the substance of prior House and Senate iterations,

See Full Page